Revolune and MindPeak to Showcase Integrated Multiplex Immunofluorescence Workflow at AACR 2026 

Revolune GmbH, a life science company, has announced it will exhibit at the American Association for Cancer Research (AACR) Annual Meeting 2026 together with MindPeak, a leader in AI-powered pathology analysis. It is focused on simplifying spatial biology through streamlined multiplex immunofluorescence (mIF) reagents. 

Technological advancement enables researchers to approach a design to simplify complex spatial biology workflow by combining Revolune's multiplex IF reagents with MindPeak's advanced image analysis solutions to generate high-quality multiplex tissue data and rapidly extract meaningful biological insights. 

According to Towards Healthcare, the multiple immunohistochemistry market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 4.29 billion in 2026 to approximately USD 11.72 billion by 2035, representing a compound annual growth rate (CAGR) of 11.8% from 2026 to 2035. Growth is driven by the rise of targeted therapies, which require companion diagnostics to identify specific biomarkers, fueling the adoption of multiplex IHC assays to guide tailored treatment decisions. The adoption of automated staining platforms and AI-driven image analysis increases laboratory efficiency, improves consistency, and reduces human error.  

CEO of Revolune, Florian Leiss, said that spatial biology requires both robust experimental workflows and reliable data interpretation with MindPeak's powerful AI-based analysis capabilities, we can help researchers simplify the path from tissue sample to actionable spatial insight. 

About MindPeak 

Mindpeak's Impact, the demand for medical image analysis is growing rapidly, but the number of cancer experts remains the same, resulting in growing workloads per specialist. It helps cancer experts meet this challenge and also build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. 

It meets clinical routine and regulatory standards, with certifications and milestones reflecting a commitment to safety, reproducibility, and global deployment. The company's work is driven by a shared mindset of curiosity, ownership, and the ambition to build AI that truly works in healthcare. Its commitment to advancing precision in cancer diagnostics is evident in its collaboration across disciplines and end-to-end ownership. 

A recent report by Towards Healthcare highlights that the multiple immunohistochemistry Market is witnessing growth due to the adoption of automated stainers, digital imaging, and AI-powered image analysis, which is reducing manual errors, improving efficiency, and increasing throughput in hospitals and laboratories. The growing aging population and higher rates of chronic diseases necessitate rapid and accurate diagnostic tools.